Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

MLA

Spelman T., et al. “Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.” PharmacoEconomics, vol. 40, Dec. 2021, pp. 323–39. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....96be584d0ecc5732cd6a9042f3e3c85d&authtype=sso&custid=ns315887.

APA

Spelman T., Herring W. L., Zhang Y., Tempest M., Pearson I., Freudensprung U., Acosta C., Dort T., Hyde R., Havrdova E., Horakova D., Trojano M., De Luca G., Lugaresi A., Izquierdo G., Grammond P., Duquette P., Alroughani R., Pucci E., … Luca G. (2021). Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. PharmacoEconomics, 40, 323–339.

Chicago

Spelman T., Herring W. L., Zhang Y., Tempest M., Pearson I., Freudensprung U., Acosta C., et al. 2021. “Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.” PharmacoEconomics 40 (December): 323–39. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....96be584d0ecc5732cd6a9042f3e3c85d&authtype=sso&custid=ns315887.